Asston Pharmaceuticals Appoints New CFO and Directors
Asston Pharmaceuticals Limited announced several key appointments following a board meeting held on March 30, 2026. The company appointed Mr. Sumit Pawar as Chief Financial Officer, effective March 30, 2026. Additionally, Mr. Yashvardhan Tupe and Mr. Sandip Sharma were appointed as Additional Non-Executive Director and Additional Non-Executive Independent Director, respectively, also effective March 30, 2026.The board also approved the date and notice for an Extraordinary General Meeting scheduled for April 28, 2026, at 12:30 PM, to be held via Video Conferencing (VC) or Other Audio Visual Means (OAVM).
Details of Appointments:
| Particulars | Mr. Sumit Pawar | Mr. Yashvardhan Tupe | Mr. Sandip Sharma | |
|---|---|---|---|---|
| 1 | Reason for Change | Appointment | Appointment | Appointment |
| 2 | Date of Appointment | March 30, 2026 | March 30, 2026 | March 30, 2026 |
| 3 | Brief Profile | Mr. Pawar is a Commerce graduate with over 3 years of experience in finance and accounting management. | Mr. Tupe holds a Bachelor's degree in Mechanical Engineering and a Master of Science in Management and International Business. | Mr. Sharma is a qualified Company Secretary with over two years of experience in corporate law, governance, and regulatory compliance. |
| 4 | Disclosure of Relationships | Not related to any Director | Not related to any Director | Not related to any Director |
Mr. Pawar, Mr. Tupe, and Mr. Sharma are not related to any existing directors on the board. The company's CIN is U24304MH2019PLC324187.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.